These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25308528)

  • 61. Vitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells.
    Boniface K; Seneschal J
    Exp Dermatol; 2019 Jun; 28(6):656-661. PubMed ID: 30636075
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
    Kroll TM; Bommiasamy H; Boissy RE; Hernandez C; Nickoloff BJ; Mestril R; Caroline Le Poole I
    J Invest Dermatol; 2005 Apr; 124(4):798-806. PubMed ID: 15816839
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Autoimmune etiology of generalized vitiligo.
    Le Poole IC; Luiten RM
    Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Vitiligo: current medical and scientific understanding.
    Boissy RE; Nordlund JJ
    G Ital Dermatol Venereol; 2011 Feb; 146(1):69-75. PubMed ID: 21317859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of interleukin-17 in the pathogenesis of vitiligo.
    Bassiouny DA; Shaker O
    Clin Exp Dermatol; 2011 Apr; 36(3):292-7. PubMed ID: 21198791
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Role of T
    Frączek A; Owczarczyk-Saczonek A; Placek W
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443482
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Autoimmunity in vitiligo: Therapeutic implications and opportunities.
    Khaitan BK; Sindhuja T
    Autoimmun Rev; 2022 Jan; 21(1):102932. PubMed ID: 34506987
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulatory T cells in multiple sclerosis and myasthenia gravis.
    Danikowski KM; Jayaraman S; Prabhakar BS
    J Neuroinflammation; 2017 Jun; 14(1):117. PubMed ID: 28599652
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Current remedies for vitiligo.
    Abu Tahir M; Pramod K; Ansari SH; Ali J
    Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Foxp3, Regulatory T Cell, and Autoimmune Diseases.
    Tao JH; Cheng M; Tang JP; Liu Q; Pan F; Li XP
    Inflammation; 2017 Feb; 40(1):328-339. PubMed ID: 27882473
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.
    Mantovani S; Garbelli S; Palermo B; Campanelli R; Brazzelli V; Borroni G; Martinetti M; Benvenuto F; Merlini G; della Cuna GR; Rivoltini L; Giachino C
    J Invest Dermatol; 2003 Aug; 121(2):308-14. PubMed ID: 12880423
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Physiopathology and genetics of vitiligo.
    Passeron T; Ortonne JP
    J Autoimmun; 2005; 25 Suppl():63-8. PubMed ID: 16298511
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans.
    Bacher P; Heinrich F; Stervbo U; Nienen M; Vahldieck M; Iwert C; Vogt K; Kollet J; Babel N; Sawitzki B; Schwarz C; Bereswill S; Heimesaat MM; Heine G; Gadermaier G; Asam C; Assenmacher M; Kniemeyer O; Brakhage AA; Ferreira F; Wallner M; Worm M; Scheffold A
    Cell; 2016 Nov; 167(4):1067-1078.e16. PubMed ID: 27773482
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Accelerating bleaching in vitiligo: balancing benefits versus risks.
    Seneschal J; Boniface K; Ezzedine K; Taieb A
    Exp Dermatol; 2014 Dec; 23(12):879-80. PubMed ID: 25039467
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vitiligo: A focus on pathogenesis and its therapeutic implications.
    Bergqvist C; Ezzedine K
    J Dermatol; 2021 Mar; 48(3):252-270. PubMed ID: 33404102
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection of antibodies to melanocytes in vitiligo by western immunoblotting.
    Hann SK; Shin HK; Park SH; Reynolds SR; Bystryn JC
    Yonsei Med J; 1996 Dec; 37(6):365-70. PubMed ID: 9048487
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Coexistent skin lesions of vitiligo and psoriasis vulgaris. Immunohistochemical analyses for IL-17A-producing cells and regulatory T cells.
    Ono S; Tanizaki H; Otsuka A; Endo Y; Koyanagi I; Kataoka TR; Miyachi Y; Kabashima K
    Acta Derm Venereol; 2014 May; 94(3):329-30. PubMed ID: 24129673
    [No Abstract]   [Full Text] [Related]  

  • 79. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.
    Rezk AF; Kemp DM; El-Domyati M; El-Din WH; Lee JB; Uitto J; Igoucheva O; Alexeev V
    J Invest Dermatol; 2017 May; 137(5):1126-1134. PubMed ID: 28132854
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo.
    Abdallah M; Lotfi R; Othman W; Galal R
    Int J Dermatol; 2014 Aug; 53(8):940-6. PubMed ID: 24527781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.